Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Clinical effect of CYP2C95/6 genotype on a patient's warfarin dose requirement.

Pharmacogenomics - 1 Jul 2017

Quinn Alison Lh, Liko Ina, Lee James C

Abstract excerpt

We describe a 38-year-old African-American female treated with warfarin for acute bilateral pulmonary emboli who is a carrier of two rare CYP2C9 variant alleles, *5 and *6, along with VKORC1 -1639GG and CYP4F2 433Val/Val genotypes. Warfarin was dosed according to the hospital's Personalized Medicine Program recommendations of 5-6 mg/day for the first 6 days, and reduced to 2.5 mg/day starting on day 8 and...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Alleles
Share to Anticoagulants
Share to Cytochrome P-450 CYP2C9

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Dose-Response Relationship, Drug

Share to Genotype

Share to Pharmacogenomic Variants

Share to Pulmonary Embolism

Share to Warfarin

Source

Identifiers

PMID: 28685643
DOI: 10.2217/pgs-2017-0059

Genes

VKORC1

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026. Manifest publication-graph-cohort-2026-09-05.1.

Source receipt: pubmed, retrieved 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Clinical effect of CYP2C9*5/*6 genotype on a patient's warfarin dose requirement.PMID 28685643Read ↗

Effect of CYP2C9 *11/*11 genotype on initial and long-term warfarin dose requirement and therapeutic response.Semantic proximity Read ↗

CYP2C9*8 is Prevalent Among African–Americans: Implications for Pharmacogenetic DosingSemantic proximity Read ↗

Clinical Pharmacogenetics Implementation Consortium Guidelines for CYP2C9 and VKORC1 genotypes and warfarin dosing.Semantic proximity Read ↗

Warfarin Dosing in Patients With CYP2C9*5 Variant Alleles.Semantic proximity Read ↗

Genetic and clinical predictors of warfarin dose requirements in African Americans.Semantic proximity Read ↗

Role of pharmacogenomics in the management of traditional and novel oral anticoagulants.Semantic proximity Read ↗

Warfarin pharmacogenomics.Semantic proximity Read ↗

Anticoagulation endpoints with clinical implementation of warfarin pharmacogenetic dosing in a real-world setting: A proposal for a new pharmacogenetic dosing approach.Semantic proximity Read ↗

Warfarin dose requirements in a patient with the CYP2C9*14 allele.Semantic proximity Read ↗

CYP4F2 genetic variant alters required warfarin dose.Semantic proximity Read ↗

Integrating genomic based information into clinical warfarin (Coumadin) management: an illustrative case report.Semantic proximity Read ↗

The future of warfarin pharmacogenetics in under-represented minority groups.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.